Integrated BioPharma, Inc. filed a Form 10-Q with the SEC on November 13, 2026, covering the three months ended September 30, 2026, reporting a net loss of $691 thousand compared with net income of $123 thousand in the same quarter a year earlier.

Key Highlights

  • Net loss of $691 thousand for the three months ended September 30, 2026, versus net income of $123 thousand in the prior-year period, according to the filing.
  • Net sales fell to $9,913 thousand from $12,689 thousand in the three months ended September 30, 2025, as reported.
  • Gross loss of $112 thousand in the current quarter, compared with gross profit of $1,019 thousand a year earlier, with cost of sales at $10,025 thousand exceeding net sales.
  • Basic and diluted net loss per share of $(0.02) for the quarter, based on weighted average shares outstanding of 31,059,610.
  • Total assets of $24,027 thousand as of September 30, 2026, down from $25,338 thousand at June 30, 2026.
  • Cash position of $3,116 thousand as of September 30, 2026, compared with $4,471 thousand at June 30, 2026.
  • 31,059,610 shares of common stock outstanding as of November 13, 2026, at a par value of $0.002 per share.

Integrated BioPharma's September 2026 Quarter: Sales Decline and Gross Loss

According to the filing, Integrated BioPharma, Inc. (Delaware-incorporated, headquartered at 225 Long Ave., Hillside, New Jersey 07205) reported net sales of $9,913 thousand for the three months ended September 30, 2026, a decline from $12,689 thousand in the comparable prior-year period. Cost of sales for the quarter was $10,025 thousand, exceeding net sales and producing a gross loss of $112 thousand, against a gross profit of $1,019 thousand in the three months ended September 30, 2025.

Selling and administrative expenses were $849 thousand in the current quarter, essentially flat compared with $856 thousand in the prior-year period, the filing disclosed. The resulting operating loss was $961 thousand, versus operating income of $163 thousand a year earlier. Other income, net, was $38 thousand, and the company recorded an income tax benefit of $232 thousand, bringing the net loss to $691 thousand. The filing also reported a deferred tax asset, net, of $3,315 thousand as of September 30, 2026, up from $3,079 thousand at June 30, 2026.

On the balance sheet, total current assets stood at $15,976 thousand as of September 30, 2026, including accounts receivable of $3,720 thousand (less an allowance for credit losses of $20 thousand), inventories of $8,545 thousand, and cash of $3,116 thousand. Total liabilities were $7,012 thousand, down from $7,671 thousand at June 30, 2026. The filing notes that operating lease right-of-use assets include $2,427 thousand with a related party, and that certain operating lease liabilities include amounts due to a related party. The company is classified as a smaller reporting company and a non-accelerated filer. No securities are registered pursuant to Section 12(b) of the Exchange Act, the filing states.

What Was Disclosed

Integrated BioPharma filed its quarterly report for the period ended September 30, 2026, disclosing a net loss of $691 thousand, net sales of $9,913 thousand, a gross loss of $112 thousand, and total assets of $24,027 thousand, with 31,059,610 common shares outstanding.